NO861682L - Derivater av kinuklidin. - Google Patents

Derivater av kinuklidin.

Info

Publication number
NO861682L
NO861682L NO86861682A NO861682A NO861682L NO 861682 L NO861682 L NO 861682L NO 86861682 A NO86861682 A NO 86861682A NO 861682 A NO861682 A NO 861682A NO 861682 L NO861682 L NO 861682L
Authority
NO
Norway
Prior art keywords
derivatives
alkyl
kinuclidine
aryl
hydrogen
Prior art date
Application number
NO86861682A
Other languages
English (en)
Other versions
NO173785B (no
NO173785C (no
Inventor
Abraham Fisher
Ishai Karton
Eliahu Heldman
Aharon Levy
Yona Grunfeld
Original Assignee
Israel Inst Biolog Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL75166A external-priority patent/IL75166A/xx
Application filed by Israel Inst Biolog Res filed Critical Israel Inst Biolog Res
Publication of NO861682L publication Critical patent/NO861682L/no
Publication of NO173785B publication Critical patent/NO173785B/no
Publication of NO173785C publication Critical patent/NO173785C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
NO861682A 1985-05-10 1986-04-29 Analogifremgangsmaate for fremstilling av farmasoeytisk virksomme kinuklidinderivater samt mellom-produkt for fremstillingen NO173785C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL75166A IL75166A (en) 1985-05-10 1985-05-10 2-substituted spiro(1,3-oxathiolane-5,3-quinuclidine)derivatives,their preparation and pharmaceutical compositions containing them and 3-hydroxy-3-mercaptomethylquinuclidine as intermidiate therefor
IL7756886 1986-01-10

Publications (3)

Publication Number Publication Date
NO861682L true NO861682L (no) 1986-11-11
NO173785B NO173785B (no) 1993-10-25
NO173785C NO173785C (no) 1994-02-02

Family

ID=26321442

Family Applications (1)

Application Number Title Priority Date Filing Date
NO861682A NO173785C (no) 1985-05-10 1986-04-29 Analogifremgangsmaate for fremstilling av farmasoeytisk virksomme kinuklidinderivater samt mellom-produkt for fremstillingen

Country Status (9)

Country Link
US (1) US4855290A (no)
EP (1) EP0205247B1 (no)
JP (2) JPH0725767B2 (no)
AT (1) ATE83485T1 (no)
CA (1) CA1311479C (no)
DE (1) DE3687288T2 (no)
DK (1) DK173084B1 (no)
ES (1) ES8703461A1 (no)
NO (1) NO173785C (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816111B2 (ja) * 1987-07-21 1996-02-21 石原産業株式会社 トランス型２−メチルスピロ（１，３−オキサチオラン−５，３’）キヌクリジン又はこれらの酸付加塩の異性化方法
US4861886A (en) * 1987-07-10 1989-08-29 Ishahara Sangyo Kaisha Ltd Method for isomerization of trans-form 2-methylspiro (1,3-oxathiolane-5,3')q
IL87234A (en) * 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US5106831A (en) * 1987-08-13 1992-04-21 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia
US4981858A (en) * 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
DE3853758T2 (de) * 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US4900830A (en) * 1987-10-28 1990-02-13 Israel Institute For Biological Research Process for labelling sulfur-containing compounds
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US4985560A (en) * 1990-01-12 1991-01-15 American Home Products Corporation Pyridazino(4,5-b)indolizines
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5407938A (en) * 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5268687A (en) * 1990-07-30 1993-12-07 Spectrum Sciences B.V. Laser scanning apparatus
JP2761973B2 (ja) * 1990-08-28 1998-06-04 雪印乳業株式会社 粉砕容易なシス‐２‐メチルスピロ（１，３‐オキサチオラン‐５，３′）キヌクリジン塩酸塩１／２水和物の製造方法
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
JPH06239861A (ja) * 1993-02-17 1994-08-30 Kanegafuchi Chem Ind Co Ltd 二環式含チッ素化合物
JP2983141B2 (ja) * 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
US5571918A (en) * 1994-05-19 1996-11-05 Ishihara Sangyo Kaisha Ltd. Method for producing 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
EP1152760B1 (en) * 1999-02-09 2007-03-28 UAB Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6433168B1 (en) 1999-07-26 2002-08-13 Sumika Fine Chemicals Co., Ltd. Highly pure phenothiazine compound, production method thereof, production method of intermediate therefor, and hydrate and novel crystal as starting materials for the intermediate
BR0309875A (pt) * 2002-05-03 2007-04-10 Israel Inst For Biolog Res Isr métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
CN1829721A (zh) * 2003-07-08 2006-09-06 阿斯利康(瑞典)有限公司 对α7烟碱乙酰胆碱受体具有亲和力的螺[1－氮杂二环[2.2.2]辛烷－3,5’－噁唑烷]－2’－酮衍生物
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
KR20070090922A (ko) * 2004-12-15 2007-09-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008073067A1 (en) * 2006-08-02 2008-06-19 Janssen Pharmaceutica N.V. Novel spiro-quinuclidinyl derivatives for the treatment of the central nervous system disorders
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8080663B2 (en) * 2007-04-04 2011-12-20 Apotex Pharmachem Inc Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine
EP2167071B1 (en) 2007-06-13 2020-03-18 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
US20100210604A1 (en) * 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US9034891B2 (en) 2009-01-26 2015-05-19 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
AU2010207486B2 (en) 2009-01-26 2013-03-07 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5452165B2 (ja) * 2009-10-23 2014-03-26 第一ファインケミカル株式会社 キヌクリジン類の製造法
US8450487B2 (en) * 2010-06-08 2013-05-28 Apicore, Llc Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN104892619A (zh) * 2015-06-26 2015-09-09 大道隆达（北京）医药科技发展有限公司 一种药物中间体的制备方法
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
JP2019052093A (ja) * 2016-02-01 2019-04-04 宇部興産株式会社 ２−メチルスピロ（１，３−オキサチオラン−５，３’）キヌクリジン硫酸塩の製造方法
MX383581B (es) 2016-10-05 2025-03-14 Nsc Therapeutics Gmbh Polimorfos cristalinos de un agonista del receptor muscarinico de acetilcolina.
US12201619B2 (en) 2018-03-22 2025-01-21 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
CN108659004B (zh) * 2018-07-12 2020-11-10 福安药业集团重庆博圣制药有限公司 奥拉西坦异构体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1301254A (no) * 1971-07-08 1972-12-29
FR2146962A1 (en) * 1971-07-28 1973-03-09 Yoshitomi Pharmaceutical Aza-spirodecanones - useful in treating gastric disorders
IL48453A (en) 1975-11-11 1980-06-30 Purdue Frederick Co Substituted 6-oxa-1-azatricyclo-(6.2.2.0 )dodecan-5-ones and 1,4-ethano-5-oxo octa (or decahydro)quinoline,their preparation and pharmaceutical compositions containing them
IL48452A (en) * 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
IL75166A (en) 1985-05-10 1989-05-15 Israel Inst Biolog Res 2-substituted spiro(1,3-oxathiolane-5,3-quinuclidine)derivatives,their preparation and pharmaceutical compositions containing them and 3-hydroxy-3-mercaptomethylquinuclidine as intermidiate therefor

Also Published As

Publication number Publication date
JPS61280497A (ja) 1986-12-11
DE3687288D1 (de) 1993-01-28
CA1311479C (en) 1992-12-15
JPH0725767B2 (ja) 1995-03-22
NO173785B (no) 1993-10-25
NO173785C (no) 1994-02-02
DK196686A (da) 1986-11-11
EP0205247A3 (en) 1988-02-03
DE3687288T2 (de) 1993-04-15
EP0205247A2 (en) 1986-12-17
DK196686D0 (da) 1986-04-29
JPH07223953A (ja) 1995-08-22
ES554280A0 (es) 1987-03-01
US4855290A (en) 1989-08-08
ATE83485T1 (de) 1993-01-15
EP0205247B1 (en) 1992-12-16
ES8703461A1 (es) 1987-03-01
DK173084B1 (da) 1999-12-27

Similar Documents

Publication Publication Date Title
NO861682L (no) Derivater av kinuklidin.
SE7703263L (sv) Forfarande for framstellning av nya acetohydroxaminsyror
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
DK365184D0 (da) 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika
FI875059L (fi) Foereningar.
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
SE8302694D0 (sv) Immunomodulating agent
FI822203A0 (fi) Nya 2-aryl-3,4-diaza-bicyklo/4,n,0/-alken-(2)-oner-(5), foerfarande foer deras framstaellning och dessa innehaollande laekemedel
SE7903976L (sv) Nya purinderivat anvendbara sasom icke-adrenenergiska bronkodilatorer
BG42835A3 (bg) Метод за получаване на производни на тиазолилоцетна киселина
NO167746C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive muramylpeptidderivater.
DK314483A (da) Peenem-derivater, fremgangsmaade til fremstilling deraf samt deres anvendelse som laegemidler
DE3675778D1 (de) (2-amino-4-aryl-thiazol-5-yl)aethanol, und deren derivate mit diuretischer aktivitaet und verfahren zu deren herstellung.
ES2055708T3 (es) Peptidos.
ES475565A1 (es) Un procedimiento para la preparacion de nuevos derivados de indol
SE8803765D0 (sv) Nya isopolypeptider samt foerfarande foer framstaellning av desamma
FI810145L (fi) Nya substituerade 1,8-dihydroxi-9-(10h)antracenoner foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel
ES516361A0 (es) "procedimiento para la preparacion de un diisocianato".
ATE22557T1 (de) Bicyclo(4.2.0)oktatriene-1,3,5 derivate, verfahren zu deren herstellung und deren therapeutische anwendung.
FR2374296A1 (fr) Derives de l'acide phtalique porteurs de groupes alcenylamino
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
DK119886A (da) Hidtil ukendte carbacykliner, fremgangsmaade til deres fremstillingog deres anvendelse som laegemiddel
FI841992A0 (fi) Substituerade isokinolinderivat.
SE8800846L (sv) Optiskt aktiva oxo-isoindolinderivat
DK52383D0 (da) Fremgangsmade til fremstilling af carbacyklinderivater

Legal Events

Date Code Title Description
MK1K Patent expired